Drugs / SB-509
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 24 trials | ||||||
| Phase 2 | NCT01079325 | Nov 2009 → May 2015 | diabetic polyneuropathy, type 1 diabetes mellitus, type 2 diabetes mellitus | Sangamo Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT00665145 | Jan 2008 → Oct 2009 | diabetic polyneuropathy, type 1 diabetes mellitus, type 2 diabetes mellitus | Sangamo Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT00476931 | May 2007 → Jul 2010 | diabetic polyneuropathy, type 1 diabetes mellitus, type 2 diabetes mellitus | Sangamo Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT00406458 | Nov 2006 → Dec 2008 | diabetic polyneuropathy, type 1 diabetes mellitus, type 2 diabetes mellitus | Sangamo Therapeutics | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00748501 Comparator | Sep 2008 → Jun 2010 | amyotrophic lateral sclerosis | Sangamo Therapeutics | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SB-509 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00406458 ↗ |
| Action | Activate | “This protein causes your cells to increase production of another protein called vascular endothelial growth factor (VEGF)” NCT00406458 ↗ |
| Route | Intramuscular | “Everyone in this study will receive intramuscular (IM-directly into the muscle) injections into both legs.” NCT00406458 ↗ |